ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 2 filers reported holding ARRAY BIOPHARMA INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $45,781,000 | +17.0% | 992,510 | -38.2% | 0.57% | +14.0% |
| Q1 2019 | $39,143,000 | +63.6% | 1,605,480 | -4.4% | 0.50% | +36.1% |
| Q4 2018 | $23,921,000 | +16.5% | 1,678,710 | +24.2% | 0.37% | +34.8% |
| Q3 2018 | $20,538,000 | +63.2% | 1,351,188 | +80.2% | 0.27% | +37.2% |
| Q2 2018 | $12,584,000 | +34.1% | 749,888 | +30.4% | 0.20% | +24.4% |
| Q1 2018 | $9,384,000 | +35.8% | 575,000 | +6.5% | 0.16% | +33.3% |
| Q4 2017 | $6,912,000 | -24.5% | 540,000 | -27.4% | 0.12% | -25.0% |
| Q3 2017 | $9,151,000 | +135.1% | 744,000 | +60.0% | 0.16% | +119.2% |
| Q2 2017 | $3,892,000 | -4.3% | 465,000 | +2.2% | 0.07% | -7.6% |
| Q1 2017 | $4,068,000 | -38.7% | 455,000 | -39.7% | 0.08% | -48.0% |
| Q4 2016 | $6,636,000 | +21.4% | 755,000 | -6.8% | 0.15% | +15.2% |
| Q3 2016 | $5,468,000 | +80.9% | 810,000 | -4.6% | 0.13% | +67.1% |
| Q2 2016 | $3,023,000 | +56.3% | 849,000 | +28.8% | 0.08% | +64.6% |
| Q1 2016 | $1,934,000 | – | 659,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 9,719,589 | $60,456,000 | 10.40% |
| KOPP INVESTMENT ADVISORS LLC | 2,808,537 | $17,470,000 | 6.42% |
| Redmile Group, LLC | 3,669,593 | $22,825,000 | 3.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,585,406 | $65,841,000 | 3.06% |
| QVT Financial LP | 2,878,600 | $17,905,000 | 1.22% |
| APEX CAPITAL, LLC | 2,500,000 | $15,550,000 | 1.12% |
| FBR & Co. | 113,500 | $706,000 | 1.07% |
| Artal Group S.A. | 3,000,000 | $18,660,000 | 0.61% |
| Perimeter Capital Partners, LLC | 486,478 | $3,026,000 | 0.56% |
| Orbimed Advisors | 4,831,600 | $30,053,000 | 0.54% |